Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2019

01-02-2019 | Breast Cancer | Review Article

Clinical target sequencing for precision medicine of breast cancer

Authors: Junko Tsuchida, Jami Rothman, Kerry-Ann McDonald, Masayuki Nagahashi, Kazuaki Takabe, Toshifumi Wakai

Published in: International Journal of Clinical Oncology | Issue 2/2019

Login to get access

Abstract

Precision medicine can be defined as the customization of medical treatment based on the individual genetic profile, which enables one to identify patients who respond to therapies while sparing side effects for those who do not. Breast cancer patients have been treated based on subtyping, which is considered a prototype of precision medicine. Furthermore, the development of multigene panel testing has resulted in a paradigm shift in the treatment of breast cancer. The knowledge generated from the Human Genome Project, and subsequently The Cancer Genome Atlas, has provided the concept of precision medicine, in which cancer patients can be sub-classified based on actionable driver mutations that can be selectively targeted by molecular targeted drugs and treated by appropriate molecular targeted therapies. Development of next-generation sequencing has both dramatically advanced genomic sequencing technology and revealed actionable driver mutations for individual cancer patients when applied to a clinical setting. Clinical target sequencing by next-generation sequencing enables one to formulate treatment strategies, not only by selecting a subgroup of patients who are expected to experience more effectiveness of each drug, but also by revealing patients with drug resistance based on their actionable driver mutations.
Literature
1.
2.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
3.
Katsnelson A (2013) Momentum grows to make ‘personalized’ medicine more ‘precise’. Nat Med 19:249CrossRefPubMed
4.
5.
6.
7.
8.
Mata DA, Katchi FM, Ramasamy R (2017) Precision medicine and men’s health. Am J Mens Health 11:1124–1129CrossRefPubMed
9.
Jain KK (2005) Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother 6:1463–1476CrossRefPubMed
10.
11.
12.
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMed
13.
Perou CM, Jeffrey SS, van de Rijn M et al (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96:9212–9217CrossRefPubMedPubMedCentral
14.
Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410CrossRefPubMed
15.
Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217CrossRefPubMedPubMedCentral
16.
Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedPubMedCentral
17.
Prat A, Fan C, Fernandez A et al (2015) Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med 13:303CrossRefPubMedPubMedCentral
18.
Chia SK, Bramwell VH, Tu D et al (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18:4465–4472CrossRefPubMedPubMedCentral
19.
Cheang MC, Voduc KD, Tu D et al (2012) Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 18:2402–2412CrossRefPubMedPubMedCentral
20.
Prat A, Galvan P, Jimenez B et al (2016) Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay. Clin Cancer Res 22:560–566CrossRefPubMed
21.
22.
Myers MB (2016) Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. Pharmgenomics Pers Med 9:7–16PubMedPubMedCentral
23.
Cronin M, Sangli C, Liu ML et al (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53:1084–1091CrossRefPubMed
24.
Paik S (2007) Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12:631–635CrossRefPubMed
25.
Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826CrossRefPubMed
26.
Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734CrossRefPubMed
27.
Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312CrossRefPubMed
28.
van ‘t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRefPubMed
29.
van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009CrossRefPubMed
30.
31.
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70CrossRef
32.
Dowsett M, Sestak I, Lopez-Knowles E et al (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783–2790CrossRefPubMed
33.
Beahrs OH, Carr DT, Rubin P et al (1977) AJCC cancer staging manual, 1st edn. American Joint Committee, Illinois
34.
Beahrs OH, Myers MH (1983) AJCC cancer staging manual, 2nd edn. J B Lippincott Company, Philadelphia
35.
Beahrs OH, Henson DE, Hutter RVP et al (1988) AJCC cancer staging manual, 3rd edn. J B Lippincott Company, Philadelphia
36.
Beahrs OH, Henson DE, Hutter RVP et al (1992) AJCC cancer staging manual, 4th edn. J B Lippincott Company, Philadelphia
37.
Fleming ID, Cooper JS, Henson DE et al (1997) AJCC cancer staging manual, 5th edn. Lippincott - Raven, Philadelphia
38.
Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York et alCrossRef
39.
Edge SB, Byrd DR, Compton CC et al (2009) AJCC cancer staging manual, 7th edn. Springer, New York
40.
Amin MB, Edge SB, Greene FL et al (2016) AJCC cancer staging manual, 8th edn. Springer, New York
41.
Cardoso F, van’t Veer LJ, Bogaerts J et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717–729CrossRefPubMed
42.
Su Y, Subedee A, Bloushtain-Qimron N et al (2015) Somatic cell fusions reveal extensive heterogeneity in basal-like breast cancer. Cell Rep 11:1549–1563CrossRefPubMed
43.
Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767CrossRefPubMedPubMedCentral
44.
Marotti JD, de Abreu FB, Wells WA et al (2017) Triple-negative breast cancer: next-generation sequencing for target identification. Am J Pathol 187:2133–2138CrossRefPubMed
45.
Collins FS, Green ED, Guttmacher AE et al (2003) A vision for the future of genomics research. Nature 422:835–847CrossRefPubMed
46.
47.
48.
Shendure J, Porreca GJ, Reppas NB et al (2005) Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309:1728–1732CrossRefPubMed
49.
50.
Ramanathan R, Olex AL, Dozmorov M et al (2017) Angiopoietin pathway gene expression associated with poor breast cancer survival. Breast Cancer Res Treat 162:191–198CrossRefPubMedPubMedCentral
51.
Kawaguchi T, Yan L, Qi Q et al (2017) Overexpression of suppressive microRNAs, miR-30a and miR-200c are associated with improved survival of breast cancer patients. Sci Rep 7:15945CrossRefPubMedPubMedCentral
52.
Young J, Kawaguchi T, Yan L et al (2017) Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival. Oncotarget 8:99978–99989PubMedPubMedCentral
53.
Kim SY, Kawaguchi T, Yan L et al (2017) Clinical relevance of microRNA expressions in breast cancer validated using the Cancer Genome Atlas (TCGA). Ann Surg Oncol 10:2943–2949CrossRef
54.
55.
56.
Arnedos M, Vicier C, Loi S et al (2015) Precision medicine for metastatic breast cancer–limitations and solutions. Nat Rev Clin Oncol 12:693–704CrossRefPubMed
57.
Kummar S, Williams PM, Lih CJ et al (2015) Application of molecular profiling in clinical trials for advanced metastatic cancers. J Natl Cancer Inst 107
58.
Renfro LA, Sargent DJ (2016) Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 28:34–43PubMedCentral
59.
60.
Willyard C (2013) ‘Basket studies’ will hold intricate data for cancer drug approvals. Nat Med 19:655CrossRefPubMed
61.
Schmidt KT, Chau CH, Price DK et al (2016) Precision oncology medicine: the clinical relevance of patient specific biomarkers used to optimize cancer treatment. J Clin Pharmacol 56:1484–1499CrossRefPubMedPubMedCentral
62.
Do K, O’Sullivan Coyne G, Chen AP (2015) An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol 4:31PubMed
63.
Hyman DM, Solit DB, Arcila ME et al (2015) Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today 20:1422–1428CrossRefPubMedPubMedCentral
64.
Lih CJ, Harrington RD, Sims DJ et al (2017) Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: Molecular Analysis for Therapy Choice clinical trial. J Mol Diagn 19:313–327CrossRefPubMedPubMedCentral
65.
Mullard A (2015) NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov 14:513–515CrossRefPubMed
66.
67.
68.
Lipson D, Capelletti M, Yelensky R et al (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382–384CrossRefPubMedPubMedCentral
69.
Redig AJ, Janne PA (2015) Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 33:975–977CrossRefPubMed
70.
Meric-Bernstam F, Johnson A, Holla V et al (2015) A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107
71.
Pritchard CC, Salipante SJ, Koehler K et al (2014) Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 16:56–67CrossRefPubMedPubMedCentral
72.
Frampton GM, Fichtenholtz A, Otto GA et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023–1031CrossRefPubMedPubMedCentral
73.
Wagle N, Berger MF, Davis MJ et al (2012) High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2:82–93CrossRefPubMed
74.
Nagahashi M, Wakai T, Shimada Y et al (2016) Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. Genome Med 8:136CrossRefPubMedPubMedCentral
75.
Shimada Y, Yagi R, Kameyama H et al (2017) Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Hum Pathol 66:1–9CrossRefPubMed
76.
Shimada Y, Kameyama H, Nagahashi M et al (2017) Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. Oncotarget 8:93567–93579CrossRefPubMedPubMedCentral
77.
78.
Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034CrossRefPubMed
79.
Collins DC, Sundar R, Lim JS et al (2017) Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends Pharmacol Sci 38:25–40CrossRefPubMed
80.
81.
Lavaud P, Andre F (2014) Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 12:132CrossRefPubMedPubMedCentral
82.
de Oliveira Taveira M, Nabavi S, Wang Y et al (2017) Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. J Cancer Res Clin Oncol 143:1255–1262CrossRefPubMedPubMedCentral
83.
Andre F, Hurvitz S, Fasolo A et al (2016) Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 34:2115–2124CrossRefPubMed
84.
Goel S, Wang Q, Watt AC et al (2016) Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 29:255–269CrossRefPubMedPubMedCentral
85.
Malumbres M (2016) CDK4/6 Inhibitors resTORe therapeutic sensitivity in HER2+ breast cancer. Cancer Cell 29:243–244CrossRefPubMed
86.
Tan O, Shrestha R, Cunich M et al (2018) Application of next-generation sequencing to improve cancer management: a review of the clinical effectiveness and cost-effectiveness. Clin Genet 93:533–544CrossRefPubMed
87.
Li Y, Bare LA, Bender RA et al (2015) Cost effectiveness of sequencing 34 cancer-associated genes as an aid for treatment selection in patients with metastatic melanoma. Mol Diagn Ther 19:169–177CrossRefPubMedPubMedCentral
88.
Norum J, Hagen AI, Maehle L et al (2008) Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur J Cancer 44:963–971CrossRefPubMed
89.
Muller D, Danner M, Rhiem K et al (2018) Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. Eur J Health Econ 19:341–353CrossRefPubMed
Metadata
Title
Clinical target sequencing for precision medicine of breast cancer
Authors
Junko Tsuchida
Jami Rothman
Kerry-Ann McDonald
Masayuki Nagahashi
Kazuaki Takabe
Toshifumi Wakai
Publication date
01-02-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 2/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1373-5

Other articles of this Issue 2/2019

International Journal of Clinical Oncology 2/2019 Go to the issue

Original Article

Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients

Invited Review Article

Knowledge base toward understanding actionable alterations and realizing precision oncology

Original Article

Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC)

Original Article

Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer

Original Article

Low-dose Gamma Knife radiosurgery plus whole-brain radiation therapy for patients with 5 or more brain metastases with or without meningeal dissemination

Original Article

Effect of combination of pre- and postoperative pulmonary rehabilitation on onset of postoperative pneumonia: a retrospective cohort study based on data from the diagnosis procedure combination database in Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits